Xencor, Inc. (XNCR)
| Market Cap | 2.66B +158.5% |
| Revenue (ttm) | 200.49M +33.5% |
| Net Income | -117.86M |
| EPS | -1.56 |
| Shares Out | 75.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,033,600 |
| Open | 37.07 |
| Previous Close | 37.09 |
| Day's Range | 35.34 - 37.39 |
| 52-Week Range | 10.38 - 40.60 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 42.50 (+20.06%) |
| Earnings Date | Nov 4, 2026 |
About XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase... [Read more]
Financial Performance
In 2025, Xencor's revenue was $125.58 million, an increase of 13.65% compared to the previous year's $110.49 million. Losses were -$91.92 million, -60.48% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for XNCR stock is "Buy." The 12-month stock price target is $42.5, which is an increase of 20.06% from the latest price.
News
Xencor announces initial dose-escalation data from Phase 1b study of plamotamab
Xencor (XNCR) announced initial dose-escalation data from its ongoing Phase 1b study of subcutaneous plamotamab, a bispecific CD20 x CD3 T-cell engager, in adults with rheumatoid arthritis. The data a...
Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor price target raised to $40 from $39 at Canaccord
Canaccord raised the firm’s price target on Xencor (XNCR) to $40 from $39 and keeps a Buy rating on the shares. The firm said After presenting very strong data in…
Xencor reports Q3 EPS 50c, consensus (34c)
Reports Q3 revenue $116.5M, consensus $63.0M. “Xencor’s (XNCR) lead CD3 T-cell engaging bispecific antibody, XmAb819, has demonstrated compelling clinical data in advanced clear cell renal cell carcin...
Xencor Reports Third Quarter 2026 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...
Xencor Quarterly report: Q3 2026
Xencor has published its Q3 2026 quarterly earnings report on November 4, 2026.
Xencor Earnings release: Q3 2026
Xencor released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Short Report: Xencor short interest slips as stock spikes on cancer data
Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the…
Xencor price target raised to $43 from $20 at RBC Capital
RBC Capital raised the firm’s price target on Xencor (XNCR) to $43 from $20 and keeps an Outperform rating on the shares. The company presented updated data from their XmAb819…
Xencor price target raised to $40 from $29 at Truist
Truist raised the firm’s price target on Xencor (XNCR) to $40 from $29 and keeps a Buy rating on the shares. The firm is positive on the company’s compelling ESMO…
Xencor price target raised to $40 from $29 at Truist
Truist raised the firm’s price target on Xencor (XNCR) to $40 from $29 and keeps a Buy rating on the shares. The firm is positive on the company’s compelling ESMO…
Xencor price target raised to $45 from $30 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Xencor (XNCR) to $45 from $30 and keeps an Outperform rating on the shares. Following the positive ESMO update, Xencor…
Xencor price target raised to $45 from $35 at Barclays
Barclays raised the firm’s price target on Xencor (XNCR) to $45 from $35 and keeps an Overweight rating on the shares. The firm says the “strong” data over the weekend…
Xencor Transcript: Study update
XmAb819 showed dose-related antitumor activity in heavily pretreated clear cell RCC, with ORRs of 30%, 44% and 45.5% at 100, 200 and 400 µg/kg. The 400 µg/kg dose was selected for planned 2027 pivotal development; safety was consistent across dose cohorts.
Xencor Press release: Study update
Xencor issued a press release on October 26, 2026, disclosing material business information to investors.
Xencor Slides: Study update
Xencor has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Xencor announces updated results from Phase 1 study of XmAb819
Xencor (XNCR) announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma, ccRCC.
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor to discuss results from Phase 1 study of XmAb819
Xencor (XNCR) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell…
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will hos...
Xencor price target raised to $26 from $20 at BofA
BofA raised the firm’s price target on Xencor (XNCR) to $26 from $20 and keeps a Neutral rating on the shares. Despite falling off all-time highs over the past month,…
Xencor price target raised to $35 from $27 at Barclays
Barclays raised the firm’s price target on Xencor (XNCR) to $35 from $27 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q2…
Xencor Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The session highlighted the transition to late-stage development with pivotal studies for proprietary T-cell engagers, notably ENPP3 in RCC, and a robust pipeline in oncology and immunology. Key data readouts are expected at ESMO and in phase II-B UC studies, with combination and bispecific strategies advancing.
Xencor Slides: Corporate presentation
Xencor has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Xencor price target raised to $21 from $14 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on Xencor (XNCR) to $21 from $14 and keeps a Neutral rating on the shares. The firm updated the company’s model.